People
Norm Armstrong is a partner in the Washington, D.C. office and co-chairs the firm's global antitrust practice. Norm's practice focuses on a wide range of antitrust matters including complex transactions, government civil and criminal investigations, and antitrust litigation. He also advises clients on consumer protection issues. Clients frequently call upon Norm to use his over 25 years of experience to obtain regulatory clearance for the most important, high-profile transactions.
Norm is a former deputy director of the Federal Trade Commission (FTC) Bureau of Competition. He served in this role for six years overseeing three divisions and the regional offices that investigated anticompetitive transactions and conduct in an array of industries including healthcare, technology, pharmaceuticals, retail, consumer goods, energy, and entertainment. Prior to that, Norm served as deputy assistant director of the Bureau of Competition where he co-led some of the FTC's most high profile litigation matters.
Norm is a former member of the ABA Antitrust Section's Long Range Planning Committee, co-chair of the ABA's Mergers and Acquisition Committee, and Vice Chair of the Pricing Conduct Committee. He frequently lectures on a wide range of antitrust issues and has been recognized by Legal 500 and Global Competition Review.
J.D., Howard University School of Law
B.A., University of Virginia
District of Columbia
Maryland
American Bar Association Anitrust Section
American Health Lawyers Association
February 22, 2021
Jeff Spigel and Norm Armstrong advise Quikrete, a buildings materials company, on its $2.74B acquisition of Forterra
December 1, 2020
Aaron's Completes Spin-Off Transaction
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Representing BASF in asserting antitrust counterclaims against a competing automotive component manufacturer, Ingevity Corporation.
Representing Evangelical Community Hospital in the Department of Justice’s challenge to its collaboration with Geisinger Health.
Represented Hillrom in its $375 million acquisition of Bardy Diagnostics.
See more
March 4, 2021
FTC Drops Philadelphia-area Hospital Merger Challenge
February 24, 2021
Buyers Beware: An Increased Risk of Private Merger Challenges
January 11, 2021
Second Criminal No-Poach Case Brought by DOJ
February 22, 2021
Jeff Spigel and Norm Armstrong advise Quikrete, a buildings materials company, on its $2.74B acquisition of Forterra
December 1, 2020
Aaron's Completes Spin-Off Transaction
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Representing BASF in asserting antitrust counterclaims against a competing automotive component manufacturer, Ingevity Corporation.
Representing Evangelical Community Hospital in the Department of Justice’s challenge to its collaboration with Geisinger Health.
Represented Hillrom in its $375 million acquisition of Bardy Diagnostics.
See more
March 4, 2021
FTC Drops Philadelphia-area Hospital Merger Challenge
February 24, 2021
Buyers Beware: An Increased Risk of Private Merger Challenges
January 11, 2021
Second Criminal No-Poach Case Brought by DOJ
February 22, 2021
Jeff Spigel and Norm Armstrong advise Quikrete, a buildings materials company, on its $2.74B acquisition of Forterra
December 1, 2020
Aaron's Completes Spin-Off Transaction
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
J.D., Howard University School of Law
B.A., University of Virginia
District of Columbia
Maryland
American Bar Association Anitrust Section
American Health Lawyers Association